News Headlines Now

Retinitis Pigmentosa Market, Epidemiology and Pipeline Insights: Market Drivers and Barriers Influencing the RP Market

 Breaking News
  • No posts were found

Retinitis Pigmentosa Market, Epidemiology and Pipeline Insights: Market Drivers and Barriers Influencing the RP Market

May 27
12:20 2020
Retinitis Pigmentosa Market, Epidemiology and Pipeline Insights: Market Drivers and Barriers Influencing the RP Market

Retinitis Pigmentosa Market| RP Market
According to DelveInsight, Retinitis Pigmentosa 7MM market is expected to change in the study period 2017-2030. Several pharma and biotech companies including HORA-RPE65 (Horama), AAV8-RPGR (Nightstar Therapeutics), jCell (jCyte), Renexus (NT-501; Neurotech Pharmaceuticals), and hRPC (ReNeuron Limited) are expected to enter into Retinitis pigmentosa market in the coming decade.

DelveInsight’s “Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Retinitis Pigmentosa, historical and forecasted epidemiology as well as the Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Retinitis Pigmentosa market report provides current treatment practices, emerging drugs, Retinitis Pigmentosa market share of the individual therapies, current and forecasted Retinitis Pigmentosa market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Retinitis Pigmentosa treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Click to Know More about the Report.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030

Disease Overview

Retinitis pigmentosa is a heterogeneous, progressive disease that leads to worsening of the vision with time.

Although, there is a significant variation in the age of onset, progression rate, the involvement of rod, and cone, retinal cells deterioration, however; the clinical manifestations that are kept in mind while diagnosing are night blindness, progressive loss of peripheral vision and subsequent loss of central vision.

Retinitis Pigmentosa Epidemiology

Being a rare disease, gathering and evaluating Retinitis Pigmentosa epidemiological data is rather a challenging task, and the data is often available in fragments and partial form.

As per DelveInsight’s Retinitis pigmentosa, epidemiological model, the diagnosed Retinitis Pigmentosa prevalent population in the 7MM (the US, EU5 and Japan) was observed to be 253,420 in 2017.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology:

  • Total Diagnosed Prevalent Cases of Retinitis Pigmentosa,
  • Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa,
  • Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa,
  • Subtype-Specific Diagnosed Prevalence of Syndromic and Systemic RP, and
  • Subtype-specific Diagnosed Prevalent Cases of Non-Syndromic RP in the 7MM) scenario of Retinitis Pigmentosa

Request for Sample Pages.

Retinitis Pigmentosa Market

Present available options and approaches in the Retinitis pigmentosa market are limited. Hence, a number of clinical trials are underway, and a lot of novel therapies are poised to enter the Retinitis pigmentosa therapy market.

Several pharma and biotech companies including HORA-RPE65 (Horama), AAV8-RPGR (Nightstar Therapeutics), jCell (jCyte), Renexus (NT-501; Neurotech Pharmaceuticals), and hRPC (ReNeuron Limited) are expected to enter into Retinitis pigmentosa market in the coming decade.

The robust pipeline is anticipated to bring a significant shift in the Retinitis pigmentosa market in the 7MM. Moreover, the US is expected to grab the major chunk of Retinitis pigmentosa market share as compared to other members of 7MM.

The Retinitis Pigmentosa market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Retinitis Pigmentosa market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

According to DelveInsight, Retinitis Pigmentosa 7MM market is expected to change in the study period 2017–2030.

Visit to Know More.

 

Key Highlights

  • ·         In the coming years, Retinitis Pigmentosa market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • ·         The companies and academics are working to assess challenges and seek opportunities that could influence Retinitis Pigmentosa R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
  • ·         Major players are involved in developing therapies for Retinitis Pigmentosa . Launch of emerging therapies will significantly impact the Retinitis Pigmentosa market
  • ·         A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Retinitis Pigmentosa
  • ·         Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Table of Contents

1. Key Insights

2. Executive Summary of Retinitis Pigmentosa (RP)

3. Retinitis Pigmentosa (RP): Market Overview at a Glance

4. Retinitis Pigmentosa: Disease Background and Overview

5. Case Reports

6. Epidemiology and Patient Population

7. United States Epidemiology

8. EU5 Epidemiology

9. Japan Epidemiology

10. Treatment Algorithm, Current Treatment, and Medical Practices

11. Proposed Guidelines for Retinitis Pigmentosa

12. Unmet Needs

13. Marketed Products

13.1. Luxturna: Spark Therapeutics/ Novartis

14. Emerging Therapies

15. Retinitis Pigmentosa (RP): 7MM Market Analysis

16. United States: Market Outlook

17. EU-5 countries: Market Outlook

18. Japan Market Outlook

19. Access and Reimbursement Overview of Retinitis Pigmentosa

20. Market Drivers

21. Market Barriers

22. SWOT Analysis

23. Appendix

24. DelveInsight Capabilities

25. Disclaimer

 

 

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.  

Browse through our vast repository

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: www.delveinsight.com/

Categories